Email this article Clinical biological features of mixed myeloiddiseases
- Authors: Gritsaev SV1, Abdulkadyrov KM1, Tiranova SA1, Kapustin SL1, Martynkevich IS1, Bessmeltsev SS1, Rugal VI1, Bakai MP1
-
Affiliations:
- Issue: Vol 79, No 12 (2004)
- Pages: 68-73
- Section: Editorial
- URL: https://ter-arkhiv.ru/0040-3660/article/view/29969
- ID: 29969
Cite item
Full Text
Abstract
Aim. To characterize patients with mixed myeloid neoplasias with proliferation of neutrophils, platelets
and eosinophils.
Material and methods. Examination and treatment results were analysed for patients with atypical
myeloid leukemia (n = 4), myelodysplastic syndrome (MDS, n = 1) and thrombocytosis, MDS and
eosinophilia (n = I). The examination included morphological, histological, cytogenetic and molecular
tests.
Results. One patient with atypical chronic myeloid leukemia was prior diagnosed to have primarily
MDS with a typical aberration of chromosome 5. Two other patients had an initial morphological picture
of resistant anemia with blast excess, signs of myeloproliferation and extramedullar hemopoiesis.
One and two months after the first examination they received transfusions of erythrocytic mass. Just
then they were found to have splenomegaly and leukocytosis due to proliferating and maturating forms
of neutrophils. The course of the disease in patients with MDS, thrombocytosis and normal karyotype
and in patients with MDS, eosinophilia and combined chromosomal breaks including translocation
(3;12)(q21;pl3) was characterized by resistance to standard programs of polychemotherapy and transformation
into acute myeloblasts leukemia.
Conclusion. In some cases atypical CML is a stage of a natural course of MDS. Some MDS variants
with eosinophilia and thrombocytosis should be referred to the group of mixed myeloid neoplasias.
and eosinophils.
Material and methods. Examination and treatment results were analysed for patients with atypical
myeloid leukemia (n = 4), myelodysplastic syndrome (MDS, n = 1) and thrombocytosis, MDS and
eosinophilia (n = I). The examination included morphological, histological, cytogenetic and molecular
tests.
Results. One patient with atypical chronic myeloid leukemia was prior diagnosed to have primarily
MDS with a typical aberration of chromosome 5. Two other patients had an initial morphological picture
of resistant anemia with blast excess, signs of myeloproliferation and extramedullar hemopoiesis.
One and two months after the first examination they received transfusions of erythrocytic mass. Just
then they were found to have splenomegaly and leukocytosis due to proliferating and maturating forms
of neutrophils. The course of the disease in patients with MDS, thrombocytosis and normal karyotype
and in patients with MDS, eosinophilia and combined chromosomal breaks including translocation
(3;12)(q21;pl3) was characterized by resistance to standard programs of polychemotherapy and transformation
into acute myeloblasts leukemia.
Conclusion. In some cases atypical CML is a stage of a natural course of MDS. Some MDS variants
with eosinophilia and thrombocytosis should be referred to the group of mixed myeloid neoplasias.
About the authors
S V Gritsaev
K M Abdulkadyrov
S A Tiranova
S L Kapustin
I S Martynkevich
S S Bessmeltsev
V I Rugal
M P Bakai
References
- Harris N. L., Jaffe E. S., Diebold J. et al. The World Healt Organisation classification of neoplasmas of the hematopoieti and lymphoma tissues: report of the clinical advisory committee meeting: Airlie house, Virginia, November, 1997. Haematol. J. 2000; 1: 53-66.
- Bain B. J. The relationship between the myelodysplastic syndromes and the myeloproliferative disorders. Leukemia anc Lymphoma 1999; 34: 443-449.
- Neuwirtova R., Mocikova K., Musilova J. et al. Mixed myelodysplastic and myeloproliferative syndromes. Leukemia 1996; 20: 717-726.
- Oscier D. G. Atypical chronic myeloid leukemia, a distinct clinical entitity related to the myelodysplastic syndrome? Br. J. Haematol. 1996; 92: 582-586.
- Hernandez J. M., Canzio M. C., Cuneo A. et al. Clinical, hematological and cytogenetic characteristics of atypical chronicmyeloid leukemia. Ann. Oncol. 2000; 11: 441-444.
- Kurzrock R., Bueso-Ramos С. E., Kantarjian H. et al. BCR rearrangement-negative chronic myelogenous leukemia revisited. J. Clin. Oncol. 2001; 19: 2915-2926.
- Verhoef G. E. G., Demnyuk H., Zachee P., Boogaerts M. A. Myelodysplastic syndrome evolving into a myeloproliferative disorder: one disease or two? Leukemia 1994; 8: 714-715.
- Абдулкадыров К. М., Грицаев С. В., Рукавицын О. А. и др. Случай атипичного миелодиспластического синдрома с эозинофилией и комплексными цитогенетическими изменениями t(3;12)(q21;pl3);t(16;17)(q24;ql2). Тер. арх. 2002; 7: 70-72.
- Bennet J. M., Catovsky D., Daniel M. Т. et al. The chronic myeloid leukemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid and chronic myelomonocytic leukemia. Br. J. Haematol. 1994; 87: 746-754.
- Misialek M. J., Pechet L. A diagnostic dilemma: chronic myelomonocytic leukemia versus atypical chronic myeloid leukemia. Acta Haematol. (Basel) 1997; 98: 221-227.
- Greenberg P., Cox C., LeBeau M. M. et al. International scoring system for evaluation prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079-2086.
- Hellstrom-Lindberg E., Wlllman C., Barrett A. J., Saunthararajah Y. Achievements in understanding and treatment of myelodysplastic syndromes. In: Hematology. (American Society Hematological Education Program.); 2000. 110-132.
- Del Canizo M. C., Brufau A., Mota A. et al. The value of cell cultures for the diagnosis of mixed myelodysplastic/myeloproliferative disorders. Haematologica 1998; 83: 3-7.
- Gallagher A., Darley R. L., Padua R. A. The molecular basis of myelodysplastic syndromes. Haematologica 1997; 82: 191- 204.
- Yamomoto K., Nagata K., Tsurukubo Y. et al. A novel translocation t(3;22)(q21;qll) involving 3q21 in myelodysplastic syndrome-derived overt leukemia with thrombocytosis. Leuk. Res. 2000; 24: 453-457.
- Bouscary D., Eontenay-Rouple M., Chretien S. et al. Thrombopoietin is not responsible for the thrombocytosis observed in patients with acute myeloid leukemias and the 3q21q26 syndrome. Br. J. Haematol. 1995; 91: 425-427.
- Zoccola D., Legros L., Cassuto P. et al. A discriminating screening is necessary to ascertain EVI-1 expression by RTPCR in malignant cells from the myeloid lineage without 3q26 rearrangement. Leukemia 2003; 17: 643-645.
- Cogswell P. C., Mogan R., Dunn M. et al. Mutation of the ras protooncogenes in chronic myelogenous leukemia: A high frequency of ras mutations in bcr/abl rearrangement-negative chronic myelogenous leukemia. Blood 1989; 74: 2629-2633.
- Badran A., Yoshida A., Wano Y. et al. Expression of the antiapoptotic gene survivin in chronic myeloid leukemia. Anticancer Res. 2003; 23: 589-592.
- Vardiman J. W., Harris N. L., Brunning R. D. The World Health Organisation (WHO) classification of the myeloid neoplasms. Blood 2002; 100: 2292-2302.
Supplementary files
